Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 5/20 | 0.45 |
| ▸ | GPR3 | P46089 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5152269 | 0.98 | CYP1A2 (0.48) | CYP1A2TNKS2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL6617112 | 0.88 | KDM4E (0.46) | CYP1A2TNKS2CYP2C19ALDH1A1KDM4E | |
| Trifluoroacetic Acid SCHEMBL8836855 | 0.86 | ADORA3 (0.42) | CYP1A2TNKS2CYP2C19ALDH1A1KDM4E | |
| Trifluoroacetic Acid SCHEMBL8837041 | 0.86 | ADORA3 (0.42) | CYP1A2TNKS2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL28361326 | 0.81 | CYP1A2 (0.36) | CYP1A2TNKS2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL11761275 | 0.81 | ALDH1A1 (0.56) | CYP1A2TNKS2ALDH1A1KDM4EHPGD | |
| SCHEMBL6614517 | 0.78 | TNKS2 (0.49) | TNKS2HPGDSMN1; SMN2HTTMAPK1 | |
| SCHEMBL6616116 | 0.76 | RPS6KA3 (0.50) | ALDH1A1HPGDLMNAMAPK1HSD17B10 | |
| SCHEMBL29396007 | 0.75 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDSMN1; SMN2HTT | |
| SCHEMBL37862 | 0.75 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 854 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4267539-A1 | HISTONE DEACETYLASE INHIBITORS | The University of Queensland (AU) | 2023-11-01 | — | — | EP | claimed |
| WO-2022133551-A1 | HISTONE DEACETYLASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-06-30 | — | — | WO | claimed |
| EP-3761978-A1 | INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2021-01-13 | — | — | EP | claimed |
| WO-2019173804-A1 | INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2019-09-12 | — | — | WO | claimed |
| EP-3344275-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | Aileron Therapeutics, Inc. (US) | 2018-07-11 | — | — | EP | claimed |
| WO-2017040990-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. (US) | 2017-03-09 | — | — | WO | claimed |
| EP-2726466-A1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| WO-2013006485-A1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | claimed |
| EP-1824518-A2 | DIAGNOSIS OF HYPERINSULINEMIA AND TYPE II DIABETES AND PROTECTION AGAINST SAME BASED ON PROTEINS DIFFERENTIALLY EXPRESSED IN SERUM | Ohio University (US) | 2007-08-29 | — | — | EP | claimed |
| EP-1617807-A4 | SUBSTITUTED 1,4-DIAZEPINES AND USES THEREOF | ORTHO MCNEIL PHARM INC (US) | 2007-02-21 | — | — | EP | claimed |
| US-20050227932-A1 | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2005-10-13 | — | — | US | claimed |
| US-20050069951-A1 | Identification of drugs using complementary combinatorial libraries | FOWLKES DANA M (US) | 2005-03-31 | — | — | US | claimed |
| WO-2004096134-A2 | SUBSTITUTED 1,4-DIAZEPINES AND USES THEREOF | ORTHO-MCNEIL PHARMACEUTICALS, INC. (US) | 2004-11-11 | — | — | WO | claimed |
| WO-2001030769-A2 | PROCESS FOR ALKYLATION OF BENZODIAZEPINDIONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2001-05-03 | — | — | WO | claimed |
| EP-0987266-A1 | BIPHENYL DERIVATIVES AND MEDICINAL COMPOSITIONS | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2000-03-22 | — | — | EP | claimed |
| US-5962337-A | ATTACHING AMINO-PROTECTED ALPHA AMINOACID WHICH MAY BE N-ALKYLATED TO SOLID SUPPORT VIA CARBOXYL GROUP, CLEAVING AMINO PROTECTING GROUP, ACYLATING WITH 2-AZIDOBENZOYL CHLORIDE, CYCLIZING VIA AZA-WITTIG RING CLOSURE | PHARMACOPEIA, INC. (US) | 1999-10-05 | — | — | US | claimed |
| EP-0850238-A4 | COMBINATORIAL 1,4-BENZODIAZEPIN-2,5-DIONE LIBRARY | PHARMACOPEIA INC (US) | 1998-10-07 | — | — | EP | claimed |
| EP-0850238-A1 | COMBINATORIAL 1,4-BENZODIAZEPIN-2,5-DIONE LIBRARY | PHARMACOPEIA, INC. (US) | 1998-07-01 | — | — | EP | claimed |
| WO-1997001560-A1 | COMBINATORIAL 1,4-BENZODIAZEPIN-2,5-DIONE LIBRARY | PHARMACOPEIA, INC. (US) | 1997-01-16 | — | — | WO | claimed |
| EP-0610334-A1 | NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPII b?III a? RECEPTOR. | GENENTECH INC (US) | 1994-08-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227932-A1 | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction | TP53, MDM2, TP53BP1 | CYP1A2 4408/4885TNKS2 216/4885CYP2C19 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.